Verrica Pharmaceuticals (VRCA) Cash from Operations Growth (1y) (2018 - 2026)
Verrica Pharmaceuticals (VRCA) Cash from Operations Growth (1y) (2018 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.87% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -28.96% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 42.76% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 75.58% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 151.70% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 172.77% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 56.79% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 100.14% |
| 10 | Verrica Pharmaceuticals | 102.80 Mn | 91.60 Mn | - | 7.99% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.99% |
| Mar 31, 2026 | 27.43% |
| Dec 31, 2025 | 71.36% |
| Sep 30, 2025 | 213.59% |
| Jun 30, 2025 | 38.60% |
| Mar 31, 2025 | 36.45% |
| Dec 31, 2024 | -10.73% |
| Sep 30, 2024 | 42.22% |
| Jun 30, 2024 | -250.35% |
| Mar 31, 2024 | -334.58% |
| Dec 31, 2023 | -192.83% |
| Sep 30, 2023 | -911.56% |
| Jun 30, 2023 | 34.98% |
| Mar 31, 2023 | 44.96% |
| Dec 31, 2022 | 43.04% |
| Sep 30, 2022 | 117.22% |
| Jun 30, 2022 | -387.35% |
| Mar 31, 2022 | 22.67% |
| Dec 31, 2021 | -42.61% |
| Sep 30, 2021 | -39.30% |